Abstract. In the present study, the polyherbal preparation diabegon, containing 18 plant extracts with hypoglycemic activity, was evaluated for its preventive effect during progression of type 2 diabetes in high-fructose-diet-fed rats. Oral administration of diabegon (100 mg / kg body weight) delayed development of glucose intolerance for 4 weeks in comparison with the diabetic control group, and the effect of diabegon was compared to that of the standard insulin sensitizer drug rosiglitazone. Diabegon treatment also ameliorated the elevation of glycosylated haemoglobin, liver glycogen content, plasma insulin, homeostasis model assessment, free fatty acids, triglycerides, total cholesterol, LDL-cholesterol, and VLDL-cholesterol, whereas it increased HDL-cholesterol after 56 days of treatment (P<0.05). The mechanism of action by which diabegon attenuates insulin resistance and dyslipidemia may be through induction of peroxisome proliferator-activated receptor-γ and lipoprotein lipase activity in peripheral tissues (muscles). Moreover, diabegon administration for 56 days also produced no alteration in liver and kidney function tests, which seems to indicate its non-toxicity during treatment. Our present results suggest that diabegon may be included in diabetes mellitus treatment regimens, as a drug with good antidiabetic actions but no toxic manifestations.
Introduction
Type 2 diabetes is one of the most money consuming and burdensome chronic diseases of our time and is a condition increasing in epidemic proportions throughout the world (1) . It is a serious lifestyle disorder and new treatment and / or therapeutic strategies must be developed to cure or control the progression of the disease. A number of antidiabetic regimens are available in the market, but some of these produce undesirable side affects after long term consumption (2, 3) . Consequently, there is a critical need for new therapeutic agents that target the underlying pathogenic mechanisms and are able to arrest or reverse the progression of type 2 diabetes.
In the field of phytomedicine, much interest has been focused on the development of alternative medicinal herbal preparations, which include screening of natural bioactive compounds with the ability to cure and / or delay the progression of diabetes through different unknown mechanisms (4) . These compounds may provide a safer drug for treatment of diabetes. A plethora of literature is available to document the antidiabetic effects of plants and their preparations (5 -7) . Some polyherbal preparations, viz.: Diabecon, Diabeton, Dionex, D-400, Daisulin, Diabetica, Diabetics, DiaCamp, Dia-Vite, Glucocare, Glucotize, GlucoNase, SugarMax, and Sugarloss, and so on, are also available commercially and are being used by the diabetic population, worldwide (3, 8, 9) . In a series of studies to determine the antidiabetic effects of a number of plants and herbal preparations, a new herbal formulation containing 18 plant extracts, viz.: Momordica charantia, Swertia chirata, Gymnema sylvestre, Trigonella foenumgraecum, Plumbago zeylanica, Eugena jambolana, Aegle marmelos, Terminalia chebula, Terminelia balerica, Emblica officinalis, Curcuma longa, Pterocarpus marsupium, Berberis aristata, Cytrullus culocynthis, Cyperus rotondus, Piper longum, root of Piper longum, Zingiber officinale, and Asphaltum punjabinum (Table 1) , named diabegon, was developed by Dindayal Aushadhalya Pvt, Ltd. (Gwalior, Madhya Pradesh, India). The dose-dependent (100, 150, and 200 mg / kg body weight) hypoglycemic activity of diabegon has been evaluated (unpublished data). The aim of present study was to evaluate the preventive effect of diabegon on the induction of high-fructose-diet (HFD)-induced diabetes and its mechanism of action in addition with non-toxic effects on liver and kidney.
Materials and Methods

Animals and treatment schedule
Male Wistar rats of about 6-to 8-week-old (180 ± 8.91 g body weight) were housed 2 animals per cage in a room with an ambient temperature of 20°C -25°C and 12 / 12-h light / dark cycle in the small animal house of our institute. All rats were randomly divided into four groups (n = 6 each): i) normal control group: fed with a standard diet (Table 2) ; ii) diabetic control group: fed with HFD; iii) diabegon-treated group: fed with HFD and diabegon (100 mg / kg body weight) in aqueous (32) .
## Determined by macro-Kjeldahl method (31).
solution treated daily using an intra-gastric tube; and iv) rosiglitazone-treated group: fed with HFD and rosiglitazone (60 µg / kg body weight) in aqueous solution treated daily using intra-gastric tube for 56 days. The feed and water were given ad libitum. The protein content and caloric value of the three diets were similar (Table 2) . Body weight, food and liquid intake, urine volume, and plasma and urinary glucose were measured at weekly intervals. The study protocol was approved by the University's Ethics Committee, and the rats were maintained in accordance with the National Institute of Nutrition, Indian Council of Medical Research, Hyderabad, India guidelines for the care and use of laboratory animals.
Oral glucose tolerance test (OGTT)
OGTTs were performed between 0900 -1000 h at weekly intervals during the experimental period. The rats were food deprived for 12 h prior to the administration of an oral glucose load (2 g / kg body weight, 200 g / l solution). Blood samples were drawn from the tail vein at 0, 30, 60, 90, and 120 min after glucose feeding. Glucose levels were determined using an Accu-Check Advantage Blood Glucose Monitor (Roche Group, Indianapolis, IN, USA).
Blood and tissue collection
At the end of study, blood samples were collected by in a heparinized tube (2 U / µl) by puncturing the orbital venous plexus of 12-h fasted and anesthesized (slight exposure to ether) rats. A part of the whole blood samples was used for the estimation of glycosylated haemoglobin (HbA 1c ) and free fatty acid (FFAs), and the remaining sample was centrifuged at 4500 × g for 10 min at 4°C and plasma was separated out and stored at −70°C until further analysis.
All the animals were sacrificed by cervical dislocation, and the epididymal fat pad and retroperitoneal adipose tissue overlying the psoas, soleus, and extensor digitorum longus (EDL) muscles, pancreas, and liver were removed and rinsed with chilled phosphatebuffered saline (pH 7.0) and weighed. After immediate weighing, the liver tissues were chopped into small pieces and stored at −70°C until further use.
HbA 1c , plasma insulin, and insulin resistance index HbA 1c was estimated by using a Cation-Exchange Resin Method kit (Monozyme Pvt., Ltd., Secunderabad, India). The plasma insulin was measured with an ELISA kit according to the manufacturer's instructions (Mercodia Rat Insulin; Mecordia AB, Uppsala, Sweden). Homeostasis model assessment (HOMA) was calculated by the following formula: [insulin (µU/ ml) × glucose (mmol / l) / 22.5] (10), which used as an index to measure the degree of insulin resistance.
Blood and liver tissue lipids
The total-cholesterol, triglycerides (TG), and HDLcholesterol (HDLc) were estimated by using enzymatic kits procured from Bayer Diagnostics India, Ltd. (Gujarat, India); and LDL-cholesterol (LDLc) and VLDL-cholesterol (VLDLc) were calculated by using Friedewald's equation. Blood FFA concentration was determined by the method of Itaya and Ui (11) . Briefly, 6 ml of chloroform, 0.1 ml of blood, and 2 ml of phosphate buffer (pH 6.2) were mixed in a glassstoppered test tube. After incubation for 15 min at room temperature, 3 ml of triethanolamine solution [1 mol / l triethanolamine, 1 N acetic acid, and 6.45% copper nitrate mixed in ratio of 9:1:10 (v / v / v)] was added. After mixing thoroughly, the samples were allowed to stand for 15 min. The upper layer from each tube was aspirated out. The residual chloroform layer was filtered and 0.1 ml of diethyldithiocarbamate solution was added in each tube, mixed, and optical density was immediately read against the blank at 440 nm. For calculation of FFA concentration, stearic acid was used as a standard.
The tissue fat was extracted as per the method of Folch et al. (12) . For this, the small pieces of tissues were macerated in 4 vol chloroform-methanol (2:1) using a glass mortar and pestle. Fat was extracted by keeping at the sample at 4°C for 24 h. The extract was centrifuged at 3,000 × g for 10 min. The supernatant was dried by using a Heto vacuum centrifuge. The residues obtained were dissolved in suitable volumes of methanol and used for the estimation of total cholesterol and TG as described above.
Estimation of liver glycogen content
Liver glycogen content was determined using the method reported by Van der Vies (13). Liver tissue (200 mg) was finely ground with 20 ml of 5% TCA in a homogenizer and protein precipitate was filtered. Clear filtrate (2 ml) was pipetted out into a 20-ml calibrated test tube and then 10 N KOH (2 ml) was added. This tube was placed in a boiling water bath for 1 h. After cooling, 1 ml of glacial acetic acid was added to neutralize the excess of alkali and fluid brought up to the mark with water. Slowly, 2 ml of solution from the previous step was added to a test tube containing 4 ml of anthrone reagent, which was placed in cold water to prevent excessive heating. After thorough mixing, the tube was placed in a boiling water bath for exactly 10 min for the development of colour and cooled with running tap water. The optical density was read within 2 h in a spectrophotometer (SPECORD 200; Analyjetika, Germany) at 650 nm against a blank that was prepared by subjecting 2 ml of 5% TCA instead of sample to the same procedure.
Lipoprotein lipase (LPL) activity
LPL activity was measured in muscle extract according to the procedure of Grinberg and coworkers (14) . The heparin-releasable LPL activity of an aliquot (100 ml) of the tissue extract was assayed for LPL activity (15) . One unit of enzyme activity is the amount of enzyme that releases 1 mmol of oleate / min at 25°C.
Western blot analysis
Each quadriceps muscle was homogenized in a solubilizing buffer containing 20 mmol / l Tris, 1 mmol / l Na 3 VO 4 , 1 mmol / l phenylmethylsulfonyl fluoride (PMSF), and 50 mmol / l NaF (pH 7.5) for 30 min at 4°C. The tissue lysates were centrifuged to remove insoluble materials. For Western blot analysis, each sample (20 µg protein / lane) was denatured by boiling in Laemmli sample buffer containing 100 mmol / l dithiothreitol and resolved by SDS-PAGE. The protein bands were transferred to nitrocellulose membrane by electroblotting in Towbin buffer containing 0.02% SDS and 20% methanol. For immunoblotting, the membranes were probed with specified antibodies. The blots were developed by a Western blot development kit, according to the manufacturer's instructions (GeneI, Bangalore, India).
Liver and kidney function tests
The liver function tests (aspartate transaminase (AST), alanine transaminase (ALT), plasma albumin, and total bilirubin) and kidney function tests (plasma urea and creatinine) were estimated using the E-Merck kits.
Statistical analysis
Data was subjected to analysis of variance using SPSS (version 10.1; Chicago, IL, USA). The significant differences among individual comparisons were evaluated by Duncan's Multiple Range Test (DMRT). Statistical significance was accepted at P<0.05. Area under the curve for glucose (AUC glucose ) was determined using the trapezoidal rule. The data was expressed as means ± S.E.M. of 6 animals in each group. Table 3 shows the values of body weight and various physiological parameters of normal and diabetic animals and the comparative effect of diabegon as well as rosiglitazone in HFD-fed rats. The body weight of the diabetic control animals was slightly higher than those of all the other groups; however, no effect was observed on body weight in diabegon and rosiglitazone-treated animals in comparison to the normal animals. Similarly, no significant differences were observed in daily food intake of among all the groups during whole experimental period, despite the water intake became slightly higher in diabetic control group after 28 days as compared to the others. The urinary volume was not significantly different in the normal, diabegon-, and rosiglitazone-treated groups, while it was slightly higher in the diabetic control animals during the later days of the experimental period (after 30 days). The weight of liver, pancreatic tissue, solenus, and EDL muscle among all the groups were nearly similar, whereas the epididymal and retroperitoneal fats were significantly higher in the diabetic control group than the other groups. Figure 1 summarizes the values for achieving the glucose intolerance induced by high-fructose diet and comparative delaying effect of diabegon as well as rosiglitazone in rats during 56 days of the experimental period. OGTT was impaired after 21 days in diabetic control animals, whereas it was impaired after 48 days in diabegon-treated animals after consumption of HFD. Indeed, the AUC glucose values in the diabegon-treated group at 48 day of the experimental period were 41% lower than that in the diabetic control animals, while the difference of AUC glucose values between diabegonand rosiglitazone-treated groups was not statistically significant, but these values became statistically significant after 56 days of the experimental period (P<0.05). However, the AUC glucose values of diabegon-treated animals were 24% and 20% lower than those of diabetic control and rosiglitazone-treated animals after 56 days of the treatment period, respectively.
Results
Effect on physiological parameters
Effect on OGTT
Effect on hyperglycemia, plasma insulin, insulin resistance index, and liver glycogen Oral administration of diabegon showed a more potent antihyperglycemic activity in HFD-fed rats than oral administration of rosiglitazone. The results summarized in Table 4 show that fasting blood glucose (FBG), HbA 1c , plasma insulin, HOMA, liver glycogen, and urinary glucose values in the diabetic control group were significant higher (66%, 44%, 47%, 82%, 38%, and 93%, respectively) than those in the normal group (P<0.05). After 56 days of treatment with diabegon, the treated animals exhibited 36% and 28% lower values of FBG than those of the non-treated diabetic control and rosiglitazone-treated animals, respectively. The levels of HbA 1c , plasma insulin, HOMA, liver glycogen content, and urinary glucose were significantly lower in the diabegon-treated animals than those of the diabetic control group (29%, 40%, 61%, 35%, and 71%, respectively) and rosiglitazone-treated animals (2.5%, 12%, 37%, 4%, and 42%, respectively). Similarly, rosiglitazone-treated animals also showed significantly lower values of fasting blood glucose, HbA 1c , plasma insulin, HOMA, liver glycogen content, and urinary glucose of 10%, 28%, 31%, 38%, 32%, and 80%, respectively, as compared with the diabetic control group of animals (P<0.05). Table 5 demonstrates that the plasma total cholesterol, TG, LDLc and VLDLc, and FFAs were significantly higher (35%, 52%, 50%, 52%, and 52%, respectively) while HDLc was lower (13%) in the diabetic control animals than that in the normal animals. However, these variables were significantly lower (23%, 33%, 35% 33%, and 38%, respectively) in the diabegon-treated rats than diabetic control rats; in addition, these values were lower (6%, 14%, 12%, 14%, and 25%, respectively) than those of rosiglitazone-treated animals (P<0.05). In rosiglitazone-treated rats, plasma total cholesterol, TG, LDLc, VLDLc, and FFAs were also lower (i.e., 18%, 22%, 26%, 22%, and 18%, respectively), than those of diabetic control animals. However, HDLc was higher in the diabegon-treated animals than that of the diabetic control (12%) and rosiglitazonetreated (8%) rats, respectively (P<0.05). Similarly, the hepatic total cholesterol and TG levels were significantly higher in diabetic control (37% and 61%, respectively) and rosiglitazone-treated (20% and 29%, respectively) animals than normal group (P<0.05), while no significant differences were observed between normal and diabegon-treated animals (Fig. 2) . Figure 3 shows that after 56 days feeding of HFD, LPL activity was lower (39%) in the diabetic control animals than those of normal animals; however, diabegon treatment arrested the depletion of LPL activity, so that the level in the treated animals was nearly similar to that in the normal animals. In addition, the rosiglitazone-treated animals had lower LPL activity (15%) than the normal animals, but their level was 26% higher than that of the diabetic control and significantly lower (9%) than that of diabegon-treated animals (P<0.05).
Effect on blood and liver lipids
Effect on LPL activity
Effect on peroxisome proliferator-activated receptor (PPAR)-γ levels
The protein levels of PPAR-γ were significantly lower (38%) in diabetic control animals than that in the normal group of animals (P<0.05). However, no difference was observed between diabegon-treated and normal animals. Indeed, it was slightly lower (14%) in rosiglitazone- , in comparison to the diabetic control group; and c , in comparison to the rosiglitazonetreated group. Fig. 3 . Effect of diabegon and rosiglitazone treatment on LPL activity in skeletal muscles of high-fructose-diet-fed rats. Diabegon (100 mg/kg per day) and rosiglitazone (60 µg/kg per day) were administered (i.g.) to HFD-fed Wistar rats (n = 6 per group) for 56 days. Animals were sacrificed after 12-h fasting conditions, and quadriceps muscles were collected for preparation of heparinized tissue extract and LPL activity was determined as described in the text. Values are the level of LPL activity as a percentage of the normal value (fed with standard diet without any treatment). The values are means ± S.E.M. of six animals in each group and significantly different (P<0.05):
a , in comparison to the normal group; b , in comparison to the diabetic control group; and c , in comparison to the rosiglitazone-treated group. treated animals than in the normal animals (Fig. 4) .
Effect on liver and kidney function tests
The oral administration of diabegon as well as rosiglitazone for 56 days in diabetic animals showed no variability in the parameters of liver and kidney function tests as compared to the parameters in normal animals ( Table 6 ).
Discussion
In the present study, the oral administration of diabegon showed a good preventive effect during progression of HFD-induced insulin resistance and dyslipidemia in comparison to a standard insulin sensitizer, rosiglitazone, and it's mode of action was similar to that of the thiozolidianediones (rosiglitazone). Oral administrations of diabegon delayed the induction of glucose intolerance and achievement of hyperglycemia in HFD-fed rats. Over intake of fructose impairs glucose metabolism by different mechanisms, giving a dietary model of type 2 diabetes, characterized by an impaired glucose tolerance test, hyperinsulinemia (16, 17) , hypertriglyceridemia (18) , and hypertension (19, 20) . Impaired glucose tolerance is the one of the most important predictors of type 2 diabetes in humans, which can predict the incidence of diabetes 10 -15 years before an individuals is expected to develop the disease (21) . However, in view of the growing prevalence of disease, there is a strong need of prevention strategies to treat or reverse the impaired glucose tolerance by natural and cheaper therapeutic agents. Administration of diabegon delayed the appearance of an impaired glucose tolerance test for 4 weeks, while rosiglitazone only delayed it for 2 weeks. HbA 1c is an advanced glycation end product that is produced due to hyperglycemia occuring during oxidative stress; it is produced when excess glucose reacts with the globin protein of normal haemoglobin (22) . It is a widely used marker of glucose homeostasis due to its stability over the lifetime of the RBCs. The administration of diabegon inhibited the glycosylation of haemoglobin by virtue of normoglycemic and antioxidant activities in HFD-fed rats (unpublished data), thus maintaining the HbA 1c levels near to the normal level during progression of HFDinduced diabetes.
Polydypsia and polyurea are the substantial physiological characteristics of diabetes mellitus. However in the present study, the water intake and urinary volume was significantly increased in the diabetic rats, whereas no effects were observed in the diabegon-treated as well as the rosiglitazone-treated rats. Moreover, the fat accumulation on the peripheral parts of the body is also a leading causative agent for the induction of insulin resistance (23) . Diabegon treatment also inhibited the accumulation of epididymal and retroperitoneal fat and reduced the risk of insulin resistance in peripheral tissues. This lower fat accumulation in diabegon-treated as well as rosiglitazone-treated animals may be the reason why these groups had a lower body weight than the non-treated diabetic control animals. The exact mechanism of reducing fat accumulation by diabegon treatment is not known, so further thorough studies are required.
The liver is a very important organ for regulation of the blood glucose and lipid homeostasis. Fructose is a potent regulator of glycogen synthesis and liver glucose uptake (24) . The results of present study showed that administration of diabegon to rats for six weeks inhibited the disturbance in glucose metabolism in the liver by reducing the accumulation of glycogen in liver, which might be due to induced glycogenolysis and/ or inhibited gluconeogenesis. The exposure of the liver to large quantities of fructose leads to rapid stimulation The values are means ± S.E.M. of 6 animals in each group. *The values are mg/100 g body weight.
of lipogenesis and TG accumulation due to the ability of fructose to bypass the main regulatory step of the glycolytic pathway, the conversion of glucose-6-phophate to fructose 1,6 phosphate, controlled by phophofructokinase. Thus, while glucose metabolism is negatively regulated by phosphofructokinase, fructose can continuously enter the glycolytic pathway, and fructose can uncontrollably produce glucose, lactate, and pyruvate providing glycerol and acyl portions of acyglycerol molecules, which result in high productions of TG, FFA, cholesterol, VLDL, and LDL-cholesterol (25) . The liver produces excess FFA and TG which migrate through VLDL to skeletal muscles and peripheral tissues to make them insulin resistant and results in hyperinsulinemia (26) . The administration of diabegon significantly inhibited the induction of hyperinsulinimia and insulin resistance index in HFDfed rats. Diabegon may bring about its protective effect during induction of diabetes by decreasing the blood FFA and TG; those are the leading causative agents for the induction of insulin resistance. It was clearly evidenced by the decreasing levels of plasma and liver TG and FFA in HFD-fed rats treated with diabegon. A number of other plants have also been observed to exert antidiabetic effect through reducing blood lipids such as TG (27) . This activity may be due to the presence of various bioactive constituents like saponins, flavonoids, alkaloids, tannins, catechin, and epicatechin, and so on; whether such bioactive constituents were present in the diabegon preparation was evaluated by chemical and HPLC analysis (data not shown here). The protective effect of diabegon was compared with the standard insulin sensitizer drug rosiglitazone that is widely used for treatment of type 2 diabetes mellitus. These agents have been used for many years for treatment of diabetes by recovering the insulin sensitivity of peripheral tissues by stimulating PPAR-γ (28, 29) . However in the present study, treatment with diabegon also maintained the protein levels of PPAR-γ reduction during progression of HFD-induced diabetes in rats, which was significantly higher in diabegon-treated animals than those in rosiglitazone-treated animals (P<0.05), indicating that diabegon is more effective than rosiglitazone. In addition, LPL is a central enzyme of lipid metabolism that is present in peripheral tissues and it catalyzes hydrolysis of TG (from VLDL) and produces FFAs and glycerol. However, the alteration of LPL activity leads to accumulation of VLDL and TG (30) . The feeding of HFD significantly reduced the LPL activity, but it was not significantly altered in diabegon-treated animals, although slightly reduced in rosiglitazone-treated animals. From the results of the present study, it may be concluded that the mechanism of action of diabegon is similar to that of rosiglitazone and effects of diabegon are more pronounced than those of rosiglitazone.
Toxicity studies on most of the herbal preparations have not been conducted. However, it is the general assumption that herbal preparations would have fewer side effects, but chronic consumption of large amounts and/ or prolonged consumption of traditional remedies must always be taken with caution. In the present study, the toxic effect has been investigated during 8 weeks exposure of diabegon to rats. There were no toxic effects during this period in regards to hepatotoxicity and nephrotoxicity in the present study.
Conclusions: In the present study, diabegon showed a potent inhibitory effect during progression of HFDinduced diabetes in rats as compared with the standard drug rosiglitazone. Diabetic animals treated with diabegon had lower values of HbA 1c , plasma insulin, HOMA, liver glycogen, total cholesterol, TG, LDLc, and VLDLc and higher values of HDLc, without any hepatotoxic and nephrotoxic effects. A parallel improvement of insulin sensitivity and alteration of dyslipidemia in the HFD-induced diabetic model may be due to activation of LPL activity and depletion of PPAR-γ protein levels that are maintained at the normal level by the treatment of diabegon. However, diabegon can be used for the treatment of prediabetic conditions, which can delay the incidence of diabetes and also may be used for diabetes treatment as a safer drug.
